Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Ricci A.D.; Grilli G.; Greco A.; Montironi R.; Ardizzoni A.; Massari F., Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis, «IMMUNOTHERAPY», 2021, 13, pp. 783 - 793 [Scientific article]
Puglisi F.; Gerratana L.; Lambertini M.; Ceppi M.; Boni L.; Montemurro F.; Russo S.; Bighin C.; De Laurentiis M.; Giuliano M.; Bisagni G.; Durando A.; Turletti A.; Garrone O.; Ardizzoni A.; Gamucci T.; Colantuoni G.; Gravina A.; De Placido S.; Cognetti F.; Del Mastro L., Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer, «NPJ BREAST CANCER», 2021, 7, Article number: 82 , pp. 1 - 9 [Scientific article]Open Access
Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A., Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3), «BRITISH JOURNAL OF CANCER», 2021, 125, pp. 306 - 306 [Comment or similar]
Raschi E.; Fusaroli M.; Ardizzoni A.; Poluzzi E.; De Ponti F., Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment, «BREAST CANCER RESEARCH AND TREATMENT», 2021, 186, pp. 219 - 227 [Scientific article]Open Access
Lo Preiato V.; Salvagni S.; Ricci C.; Ardizzoni A.; Pagotto U.; Pelusi C., Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature, «REVIEWS IN ENDOCRINE & METABOLIC DISORDERS», 2021, 22, pp. 337 - 349 [Scientific article]
Ciccarese F.; Piccinino A.; Brocchi S.; Balacchi C.; Dall'Olio F.G.; Massari F.; Rihawi K.; Paccapelo A.; Ardizzoni A.; Golfieri R., Expected and non-expected immune-related adverse events detectable by CT, «EUROPEAN JOURNAL OF RADIOLOGY», 2021, 138, Article number: 109617 , pp. 1 - 7 [Scientific article]
Laprovitera N.; Salamon I.; Gelsomino F.; Porcellini E.; Riefolo M.; Garonzi M.; Tononi P.; Valente S.; Sabbioni S.; Fontana F.; Manaresi N.; D'Errico A.; Pantaleo M.A.; Ardizzoni A.; Ferracin M., Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches, «FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY», 2021, 9, Article number: 666156 , pp. 1 - 15 [Scientific article]Open Access
Angelicola, Stefania; Ruzzi, Francesca; Landuzzi, Lorena; Scalambra, Laura; Gelsomino, Francesco; Ardizzoni, Andrea; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna, IFN-γ and CD38 in Hyperprogressive Cancer Development, «CANCERS», 2021, 13, Article number: E309 , pp. 1 - 24 [Scientific article]Open Access
Massari F.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Ardizzoni A.; Santoni M., Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials, «EUROPEAN JOURNAL OF CANCER», 2021, 154, pp. 120 - 127 [Scientific article]
Massari, Francesco; Rizzo, Alessandro; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; Ardizzoni, Andrea; Santoni, Matteo, Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials, «EUROPEAN JOURNAL OF CANCER», 2021, 154, pp. 120 - 127 [Scientific article]
Comito F.; Nigro M.C.; Sperandi F.; Melotti B.; Ardizzoni A., Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab, «EUROPEAN JOURNAL OF CANCER», 2021, 146, pp. 84 - 86 [Scientific article]
Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Rosellini M.; Marchetti A.; Montironi R.; Ardizzoni A.; Massari F., Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials, «EUROPEAN UROLOGY FOCUS», 2021, 1077, pp. 1 - 8 [Scientific article]
Rizzo, Alessandro; Mollica, Veronica; Giunchi, Francesca; Dall'Olio, Filippo Gustavo; Rosellini, Matteo; Marchetti, Andrea; Franceschini, Tania; Schiavina, Riccardo; Brunocilla, Eugenio; Fiorentino, Michelangelo; Ardizzoni, Andrea; Massari, Francesco, Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience, «PATHOLOGY RESEARCH AND PRACTICE», 2021, 220, Article number: 153410 , pp. 1 - 5 [Scientific article]
Gatti, Milo; Raschi, Emanuel; Moretti, Ugo; Ardizzoni, Andrea; Poluzzi, Elisabetta; Diemberger, Igor, Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase, «VACCINES», 2021, 9, Article number: 19 , pp. 1 - 13 [Scientific article]Open Access
Laprovitera N.; Riefolo M.; Porcellini E.; Durante G.; Garajova I.; Vasuri F.; Aigelsreiter A.; Dandachi N.; Benvenuto G.; Agostinis F.; Sabbioni S.; Berindan Neagoe I.; Romualdi C.; Ardizzoni A.; Trere' D.; Pichler M.; D'Errico A.; Ferracin M., MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary, «MOLECULAR ONCOLOGY», 2021, 15, pp. 2732 - 2751 [Scientific article]Open Access
